Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here’s what you need to know.

What To Know: The preclinical studies demonstrated that BP1001-A enhances insulin sensitivity by downregulating the growth factor receptor-bound protein 2. These findings suggest BP1001-A could improve insulin-induced metabolic processes and offer a new therapeutic option for obesity-related metabolic conditions.

Following these findings, the company began animal studies to validate the efficacy of BP1001-A. Pending success, the company plans on holding a first-in-human Phase 1 clinical trial in 2025 to assess safety, pharmacokinetics, and dosing.

BPTH Price Action: Bio-Path Holdings shares were up 104.8% at $1.37 at the time of writing, according to Benzinga Pro.

Read Next:

• Even in 2023, Charlie Munger Said ‘Elon Musk Overestimates Himself’ But Credited His Success to One Key Factor

Image Via Shutterstock.